Page 69 - Priority Review News Today

/PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB),...

STOCKHOLM, March 14, 2023 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai...

Eisai is Proud to Support U.S. Veterans Living With Early Stages of Alzheimer's Disease and Will Continue to Transparently Share our High-Quality Data with the VHATOKYO, Mar 14, 2023 - (JCN Newswire) -

STOCKHOLM, March 14, 2023 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai announced today that the U.S. Veterans Health Administration (VHA) is providing coverage

/PRNewswire/ -- BioArctic ABs (publ) (NASDAQ Stockholm: BIOA B) partner Eisai announced today that the U.S. Veterans Health Administration (VHA) is providing...

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (Nasdaq: INVA) (“Innoviva”), a diversified holding company with a portfolio of royalties and other healthcare assets, today announced that the U.S. Food and Drug Administration’s (FDA) Antimicrobial Drugs Advisory Committee will convene April 17, 2023 to review dat...

/PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the U.S. Veterans Health Administration (VHA) is...

If Approved, Remestemcel-L will be the First Allogeneic “Off-the-Shelf” Cellular Medicine in the US, and the First Therapy for Children Under 12 Years Old...

The FDA has accepted for Priority Review the sBLA for Leqembi (lecanemab-irmb) to convert its accelerated approval status to a traditional approval.

The FDA has accepted for Priority Review the sBLA for Leqembi (lecanemab-irmb) to convert its accelerated approval status to a traditional approval.